Baidu
map

Circulation:吸烟增静脉血栓栓塞风险

2013-03-18 高晓方 译 医学论坛网

     英国学者的一项研究表明,在通常情况及术后,现时吸烟者的静脉血栓栓塞发病率均较高;吸烟为评估手术患者静脉血栓栓塞的另一危险因素。论文于2013年3月12日在线发表于《循环》(Circulation)。   此项大型前瞻性研究共纳入1162718例平均年龄为56岁的女性受试者,并进行了为期6年的随访。在未行手术以及术后12周情况下,评估与吸烟习惯相关的静脉血栓栓塞发病率。   结果显示

  静脉血栓

  英国学者的一项研究表明,在通常情况及术后,现时吸烟者的静脉血栓栓塞发病率均较高;吸烟为评估手术患者静脉血栓栓塞的另一危险因素。论文于2013年3月12日在线发表于《循环》(Circulation)。

  此项大型前瞻性研究共纳入1162718例平均年龄为56岁的女性受试者,并进行了为期6年的随访。在未行手术以及术后12周情况下,评估与吸烟习惯相关的静脉血栓栓塞发病率。

  结果显示,随访期间共有4630例受试者因静脉血栓栓塞而住院或死亡。在未行手术情况下,现时吸烟者的静脉血栓栓塞发病率显著高于从未吸烟者(校正相对危险度[RR] 1.38),并且重度吸烟者(≥15支/天)的相应风险显著高于轻度吸烟者(<15支/天)。现时吸烟者接受手术治疗的可能性亦高于从未吸烟者(RR 1.12)。在行手术治疗的女性中,现时吸烟者术后12周的静脉血栓栓塞发病率显著高于从未吸烟者(RR 1.16)。

血栓相关的拓展阅读:


Smoking, Surgery, and Venous Thromboembolism Risk in Women: UK Cohort Study

Background—Evidence about the effect of smoking on venous thromboembolism risk, generally and in the post-operative period, is limited and inconsistent. We examined the incidence of venous thromboembolism in relation to smoking habits, both in the absence of surgery and in the first 12 post-operative weeks in a large prospective study of UK women.

Methods and Results—During 6 years' follow-up of 1,162,718 women, mean age 56 years, 4630 were admitted to hospital for or died from venous thromboembolism. In the absence of surgery, current smokers had a significantly increased incidence of venous thromboembolism compared to never smokers (adjusted relative risk [RR]=1.38 [95% confidence interval 1.28-1.48]), with significantly greater risks in heavier than lighter smokers (RRs 1.47 [1.34-1.62] and 1.29 [1.17-1.42] for 15+ versus <15 cigarettes/day). Current smokers were also more likely to have surgery than never smokers (1.12 [1.12-1.13]). Among women who had surgery, the incidence of venous thromboembolism in the first 12 post-operative weeks was significantly greater in current than never smokers (1.16 [1.02-1.30]).

Conclusions—Venous thromboembolism incidence was increased in current smokers, both in the absence of surgery and in the 12 weeks following surgery. Smoking is another factor to consider when assessing venous thromboembolism risk in patients undergoing surgery.



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1697156, encodeId=faac169e15626, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Mar 03 17:24:00 CST 2014, time=2014-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955173, encodeId=632e19551e3b7, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Nov 23 09:24:00 CST 2013, time=2013-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770063, encodeId=32f81e700634a, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Thu May 16 04:24:00 CST 2013, time=2013-05-16, status=1, ipAttribution=)]
    2014-03-03 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1697156, encodeId=faac169e15626, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Mar 03 17:24:00 CST 2014, time=2014-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955173, encodeId=632e19551e3b7, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Nov 23 09:24:00 CST 2013, time=2013-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770063, encodeId=32f81e700634a, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Thu May 16 04:24:00 CST 2013, time=2013-05-16, status=1, ipAttribution=)]
    2013-11-23 xue8602
  3. [GetPortalCommentsPageByObjectIdResponse(id=1697156, encodeId=faac169e15626, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Mar 03 17:24:00 CST 2014, time=2014-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955173, encodeId=632e19551e3b7, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sat Nov 23 09:24:00 CST 2013, time=2013-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770063, encodeId=32f81e700634a, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Thu May 16 04:24:00 CST 2013, time=2013-05-16, status=1, ipAttribution=)]

相关资讯

Circulation:癌症患者VTE复发风险评估模型

  虽然低分子量肝素(LMWH)的长期应用是目前癌症合并静脉血栓栓塞(VTE)的标准治疗,但是否应根据个体VTE复发的风险确定治疗策略仍不明确。   Martha L等于2012年6月7日在《循环》(Circulation)杂志在线发表文章,对543例癌症患者VTE进行了一项回顾性队列研究。结果表明,通过评估癌症患者VTE复发风险,进而采取个体化抗凝治疗,可以在提高临床疗效的同时最大限

NEJM:阿哌沙班可安全降低长期VTE复发风险

        一项近2500例患者的随机试验显示,抗凝治疗静脉血栓栓塞(VTE)6个月-12个月后,进行为期12个月的两种不同剂量的阿哌沙班(Eliquis, Bristol-Myers Squibb/Pfizer)治疗,与安慰剂相比,可显著降低复发性静脉血栓栓塞风险。该研究结果发表在《新英格兰医学杂志》上。     &n

NEJM:阿司匹林可预防静脉血栓栓塞复发

  首次发作的静脉血栓栓塞(VTE)患者需要首先给予肝素治疗,接着给予数月华法林或一种新型抗凝剂治疗。此后如何治疗之前存在争论。一项来自澳大利亚的阿司匹林预防静脉血栓栓塞复发(ASPIRE)研究发现,对那些正在接受上述治疗的患者每天给予100mg的阿司匹林是个好的选择。该研究结果与去年的WARFASA研究结果一致。   两项研究汇总分析表明,阿司匹林明显减少了约1/3的VTE事件,而且还能显著降

FDA添加屈螺酮VTE风险警示标签

  4月10日,美国FDA表示将为所有含屈螺酮的避孕药添加VTE风险警示标签。   一些近期的流行病学研究报告,含有屈螺酮的避孕药与含有其他孕激素类的药物如左炔诺孕酮相比,静脉血栓栓塞事件(VTE)风险升高3倍。不过,也有其他研究未发现含屈螺酮的药物有额外VTE风险。   FDA指出,除了含有屈螺酮的药物与不含屈螺酮的药物的VTE相对危险估计不一致外,研究并没有解释可能影响处方及可能影响血栓危

Baidu
map
Baidu
map
Baidu
map